key: cord-0293030-ey443r4d
authors: Sui, Yongjun; Li, Jianping; Andersen, Hanne; Zhang, Roushu; Prabhu, Sunaina Kiran; Hoang, Tanya; Venzon, David; Cook, Anthony; Brown, Renita; Teow, Elyse; Velasco, Jason; Pessaint, Laurent; Moore, Ian N.; Lagenaur, Laurel; Talton, Jim; Breed, Matthew W.; Kramer, Josh; Bock, Kevin W.; Minai, Mahnaz; Nagata, Bianca M.; Choo-Wosoba, Hyoyoung; Lewis, Mark G.; Wang, Lai-Xi; Berzofsky, Jay A.
title: An intranasally administrated SARS-CoV-2 beta variant subunit booster vaccine prevents beta variant viral replication in rhesus macaques
date: 2021-10-20
journal: bioRxiv
DOI: 10.1101/2021.10.19.464990
sha: 3f5e05c40da4e7d658cdb200684f98b69cba9bda
doc_id: 293030
cord_uid: ey443r4d

Emerging of SARS-CoV-2 variants and waning of vaccine/infection-induced immunity poses threats to curbing the COVID-19 pandemic. An effective, safe, and convenient booster vaccine will be needed. We hypothesized that a variant-modified mucosal booster vaccine might induce local immunity to prevent SARS-CoV-2 infection at the port of entry. The beta-variant is hardest to cross-neutralize. Herein we assessed the protective efficacy of an intranasal booster composed of beta variant-spike protein S1 with IL-15 and TLR agonists in previously immunized macaques. The macaques were first vaccinated with Wuhan strain S1 with the same adjuvant. One year later, negligibly detectable SARS-CoV-2-specific antibody remained. Nevertheless, the booster induced vigorous humoral immunity including serum- and bronchoalveolar lavage (BAL)-IgG, secretory nasal- and BAL-IgA, and neutralizing antibody against the original strain and/or beta variant. Beta-variant S1-specifc CD4+ and CD8+ T cell responses were also elicited in PBMC and BAL. Following SARS-CoV-2 beta variant challenge, the vaccinated group demonstrated significant protection against viral replication in the upper and lower respiratory tracts, with almost full protection in the nasal cavity. The fact that one intranasal beta-variant booster administrated one year after the first vaccination provoked protective immunity against beta variant infections may inform future SARS-CoV-2 booster design and administration timing.

Emergence of novel SARS-CoV-2 variants of concern (VOC) threatens the efforts to 57 curb the COVID-19 pandemic. Some variants demonstrated significantly reduced neutralization 58 sensitivity to sera from convalescent and vaccinated individuals. has been the most difficult strain to neutralize so far 1 , boosting with beta variant S1 might 132 account for this improvement and suggest the potential benefit of switching antigens from the 133 original WA strain to a variant. It is noteworthy that boosting with the variant S1 still induced a 134 strong anamnestic response against the original priming Wuhan S1. 135

IgA and dimeric IgA responses in bronchoalveolar lavage (BAL) and nasal swabs were 136 also examined, as IgA, especially dimeric IgA, displays high binding affinity to pathogens, and 137 thus is more potent at preventing mucosal pathogen infections 26, 27 . Right before the one-year 138 booster, no S1 (original or beta variant)-specific IgA, or dimeric IgA responses were detected, 139 and the antibody titers were comparable to the basal levels of naïve animals ( Figure 2c ). 140

Consistent with IgG and neutralization responses, the one-year booster enhanced IgA responses 141 in nasal swab and BAL samples with similar antibody titers against S1 from the original strain 142 and the beta variant ( Figure 2c) Table 2 ). In contrast, mucosal antibody responses, including 158 S1-specific BAL IgG, IgA and dimeric IgA responses in nasal swabs, IgA responses in BAL, 159

showed correlations or trends of correlations between the original Wuhan strain and beta variant 160 (Supplementary Table 2 administration of the beta variant S1 one-year booster, even though the geometric mean titers 166 against the Wuhan strain and beta variant were generally similar. 167

Variant S1-specific cellular responses were induced after the one-year booster 168

The vaccine-induced S1-specific T cell responses in PBMC and BAL samples of the 169 vaccinated animals were evaluated by intracellular cytokine staining. S1-specific type 1 helper T 170 cell responses (Th1) and CD8 + T cell that secrete tumor necrosis factor (TNF)-a, and/or 171 interferon (IFN)-g were induced after the first vaccination ( Figure 3 ). Though the responses 172 were persistent in most of the vaccinated animals, no further enhancement of the responses was 173 observed after the second and third vaccinations. For CD8 + T cell responses, especially the 174 responses in PBMC, we observed a declining trend with each vaccination (less so in BAL). This 175 raises the concern that extensive boosters in a short period of time might burn out the SARS-176

CoV-2 -specific T cell responses. Nevertheless, the responses waned to under the detection limit 177 in most of the animals after one year. After the administration of the one-year beta-variant 178 booster, the S1-specific CD8 + T cell responses were successfully recalled in all 5 PBMC samples 179 and CD4 + responses in 4/5 ( Figure 3 ). Even though the route of the one-year booster was 180 intranasal, S1-specific CD4 + T cells were induced only in 3 BAL samples, and CD8 + T cells in 181 only two. One possibility could be the migration of antigen-specific T cell to the nasal cavity, 182 while the other could be antigen-specific T cell exhaustion caused by multiple doses of vaccine. 

As reported in the previous study 20 , the mucosal vaccine is safe. Throughout the whole 210 course of this study, we did not observe any adverse effects in the vaccinated animals. been fully established, neutralizing antibody (Nab) responses are believed to be one of the major 238 protective mechanisms 33-35 . To evaluate the durability, one study found that the half-life of Nab 239 was biphasic, with a rapid initial decline over 61 days, and then a more gradual tapering after the 240 first 2 months out to 104 days 36 , while the other study found that Nab exhibited a bi-phasic 241 decay with an extended half-life of >200 days 37 . Though prolonged humoral and cellular 242 immunity up to 10 months or one year has been reported in SARS-CoV-2-convalescent 243 individuals 38-40 , the durability of the protective immunity against SARS-CoV-2 infection 244 remains unknown. 245

The emergence of SARS-CoV-2 variants of concern might partially account for the 246 reported decreased vaccine effectiveness after 6 months 12,41 . These variants either have high 247 infectious potency or evade the immunity induced by SARS-CoV-2 infection or vaccination. 248

The beta variant has the greatest immune evasive capacity among the widespread variants 249 detected to date 1 . In this study, we have switched the S1 from original Wuhan strain to that of 250 the beta variant, which led to successful elicitation of systemic and mucosal immune responses 251 against both the original strain and the beta variant, and most importantly mediated protection 252 against subsequent SARS-CoV-2 beta variant challenge. Incorporating S1 from the beta variant 253 into the booster vaccine might account for the observed robust protection. 254 A dramatic increase in antibody titers after the one-year booster was observed (more than 255 3 log of increase compared to the highest titers one year before for serum IgG titers). This is 256 consistent with what we have found in a previous study, where the booster at 4 months induced 257 much higher quality SARS-CoV-2 specific immune responses than the booster at 3 weeks did 20 . ELISA assays were run as described before 20 . The S1-specific binding assays were coated 318 with 100 ng/well of the SARS-CoV-2 spike S1-His Recombinant Protein (Sino Biological) using 319 high-binding 96-well plates (Santa Cruz Biotechnology). After incubation at 4°C overnight, and 320 1hr. blocking with 300 μL of 2% sodium casein in 1X PBS, the concentrated BAL samples (with 321 a series of 2-fold dilutions starting from an IgA or IgG concentration of 2 μg/mL) or nasal swab 322 samples, or serially diluted serum samples (4-fold starting from a 1:150 dilution) were applied in 323 duplicate. After incubation at room temperature for 1 hr., the plates were washed four times. 324 Subsequent steps of incubation with HRP-labeled secondary antibody and TMB substrate were 325 followed as described before. For IgG and IgA binding assay, Goat Anti-Monkey IgG (alpha-326 chain specific)-HRP conjugate (1:5,000 dilutions, Alpha Diagnostic) and were used, respectively, 327 as a secondary antibody. Area under the curve, endpoint titer, and ID50 values were calculated by 328

GraphPad Prism 8 software with sigmoidal nonlinear regression. Dimeric IgA in BAL and nasal 329 swabs was measured using DuoSet ELISA Ancillary Reagent Kit 2 (R&D Systems) as described 330 before 20 . 100 ng/well of the SARS-CoV-2 spike S1 protein was coated and blocked. Original BAL 331 samples or nasal swab flow-through from vaccinated and naïve animals were added in duplicate 332 to the plates, followed by adding mouse anti-rhesus J chain [CA1L_33e1_A1a3] antibody (1:1000 333 dilutions, NIH nonhuman primate reagent resource), and Goat anti-mouse IgG-HRP conjugate 334

(1:10,000 dilutions, R&D Systems). Each step was followed by 1 hr. incubation at room 335 temperature and five washes. The frequencies of IFNg and/or TFNa-producing CD4 + and CD8 + T cells were stained and measured after stimulation with S1 for 18 hrs in PBMC and BAL samples. Dashed lines indicate the detection limits. Bars indicate medians. Blue color indicates the S1 protein or the virus from Wuhan or WA strain, and magenta color indicates from beta variant. 

Durability of mRNA-1273 vaccine-induced antibodies against SARS-428 CoV-2 variants

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to 430

Detection of a SARS-CoV-2 variant of concern in South Africa

New SARS-CoV-2 Variants -Clinical, Public 434 Health, and Vaccine Implications

Detection of B.1.351 SARS-CoV-2 Variant Strain -Zambia

Structure-Function Analyses of New SARS-CoV-2 Variants B

.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications

SARS-CoV-2 B.1.1.7 and 441 B.1.351 Spike variants bind human ACE2 with increased affinity

Reduced binding and neutralization of infection-and vaccine-induced 443 antibodies to the B.1.351 (South African) SARS-CoV-2 variant

SARS-CoV-2 501Y.V2 escapes neutralization by South African 445 COVID-19 donor plasma

Escape from neutralizing antibodies by SARS-CoV-2 spike protein 447 variants

Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine 452 through 6 Months

Significant reduction in humoral immunity among healthcare 454 workers and nursing home residents 6 months after COVID-19 BNT162b2 mRNA 455 vaccination. medRxiv

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine 457 over 6 Months

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 459 months in a large integrated health system in the USA: a retrospective cohort study

Immunological characteristics govern the 462 transition of COVID-19 to endemicity

Considerations in boosting COVID-19 vaccine immune responses

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as 466 primary or booster series in mice

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine 468 boosters in healthy adults: an interim analysis

Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus 470 macaques

A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower 472 Respiratory Tracts against SARS-CoV-2

A single dose of an adenovirus-vectored vaccine provides protection 474 against SARS-CoV-2 challenge

Intranasal vaccination with a lentiviral vector protects against SARS-476

CoV-2 in preclinical animal models

An adenovirus-vectored COVID-19 vaccine confers protection from 478 SARS-COV-2 challenge in rhesus macaques

Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-480 Env antibody response

Regulation of the polymeric immunoglobulin receptor 482 and IgA transport: new advances in environmental factors that stimulate pIgR expression 483 and its role in mucosal immunity

Immunoglobulin responses at the mucosal interface

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in 487 macaques

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in 489 Nonhuman Primates

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia 493 in rhesus macaques

Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health 495 System Workforce

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Potential SARS-CoV-2 Immune Correlates of 499 Protection in Infection and Vaccine Immunization

Immune Correlates of Protection by mRNA-1273 Immunization 501 against SARS-CoV-2 Infection in Nonhuman Primates

Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients 503 with COVID-19: an observational study

Longitudinal analysis shows durable and broad immune memory 505 after SARS-CoV-2 infection with persisting antibody responses and memory B and T 506 cells

Prolonged humoral and cellular immunity in COVID-19-recovered 508 patients

Immunological memory to SARS-CoV-2 assessed for up to 8 months 510 after infection

Protective humoral and cellular immune responses to SARS-CoV-2 512 persist up to 1 year after recovery

Viral loads of Delta-variant 515 SARS-CoV2 breakthrough infections following vaccination and booster with the 516 BNT162b2 vaccine